SPECT Imaging Response with PSMA Radionuclide Therapy ...

Louise Emmett emphasizes the importance of SPECT imaging in assessing early and interim responses to Lutetium PSMA therapy in prostate cancer.

Assessing Response to PSMA Radiopharmaceutical Therapies with ...

Understanding the relationship between lesion-absorbed dose and tumor response in 177 Lu-PSMA-617 radiopharmaceutical therapies (RPTs) ...

Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a ...

Lu-PSMA-617 is an effective and novel treatment in metastatic castration-resistant prostate cancer (mCRPC). Our ability to assess response rates ...

Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a ...

Accurate monitoring of response to 177Lu-PSMA-617 may improve patient outcomes by enabling treatment escalation, change in treatment, or a treatment holiday, ...

177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts ...

In metastatic castration-resistant prostate cancer (mCRPC), 177Lu-PSMA is an effective therapy, although treatment resistance and short response ...

Quantitative imaging for 177Lu-PSMA treatment response ... - Frontiers

Post-177Lu-PSMA SPECT/CT offers the unique opportunity of assessment of response to treatment while the therapy is ongoing, without the need to administer a ...

Early response monitoring during [177Lu]Lu-PSMA I&T therapy with ...

Our data evaluates the tumor volumetric changes from baseline to after the first therapy cycle based on quantitated SPECT/CT imaging performed ...

Fast, quantitative SPECT/CT acquisition following multiple therapy ...

The confirmation of positive or negative treatment response plays a critical role in disease management, and SPECT/CT with xSPECT Quant images ...

177Lu–Prostate-specific Membrane Antigen Radioligand Therapy in ...

Whole-body imaging with or without SPECT/CT from 4–6 hours to 7 days can confirm the correct localization of the therapeutic radiopharmaceutical ...

Imaging expression of prostate-specific membrane antigen ... - VIVO

Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant ...

Joint EANM/SNMMI procedure guideline for the use of 177 Lu ...

As PSMA-PET (or PSMA-SPECT) is a strong and relative unique factor for prediction of an individual patient's response probability to 177Lu-PSMA- ...

UroToday.com on X: "SPECT imaging response with PSMA ...

SPECT imaging response with PSMA radionuclide therapy. @drlouiseemmett presents a nuanced approach to treatment personalization, ...

SPECT/CT predicts treatment response in Pluvicto patients

SPECT/CT scans taken just four hours after patients begin lutetium-177 (Lu-177) prostate-specific membrane antigen-617 (PSMA-617) treatment ...

Assessing Response to PSMA Radiopharmaceutical Therapies with ...

Request PDF | Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection | Understanding ...

PSMA PET/CT for Response Assessment of 177Lu-PSMA Therapy

PSMA-based imaging with PET/CT, however, has not yet been integrated into therapy monitoring, but molecular imaging of the theranostic target may pave the way ...

Radiation Dosimetry in 177 Lu-PSMA-617 Therapy Using a Single ...

Dose to healthy tissues is best characterized by scanning patients in the first 2 d of treatment because of the larger degree of tracer clearance in this early ...

SPECT/CT improves management of Pluvicto patients - AuntMinnie

SPECT/CT imaging can help manage patients undergoing radiopharmaceutical therapy (RPT) with Pluvicto for advanced prostate cancer, according to a study.

Quantitative imaging for >177>Lu-PSMA treatment response ...

However, response rates and duration using 177Lu-PSMA-617 vary considerably between patients. Quantitative 177Lu SPECT imaging is one approach that may be ...

Assessing Response to PSMA Radiopharmaceutical Therapies with ...

Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection ... Authors: Surekha Yadav; Fei Jiang; Sara ...

PSMA Targeted Molecular Imaging and Radioligand Therapy for ...

In a prospective comparative trial (ProPSMA) of 302 patients with high-risk localized prostate cancer prior to RP or radiation therapy, the ...